AMS Biotechnology has added ClioCell, an ex vivo device for removing dying and dead cells, to its portfolio, which improves the viability and quality of cell populations and their subsequent productivity.
The system comprises super-paramagnetic nanoparticles coupled with proprietary elements that bind to dead and dying cells and cell debris. The resultant product selectively initiates dead-cell removal, emulating dead-cell clearance mechanisms which operate in vivo to keep tissues functioning optimally.
The Abingdon, UK-based company says the technology is step-changing, providing new opportunities to optimise cell growth, culture and storage. ClioCell has been evaluated by several independent commercial and academic research institutions working on cell culture projects. It has been successfully tested on many cell types, both human and mammalian. Cliocell can be manufactured to cGMP grade and the AMS Biotechnology team has experience of many cell types, pre and post thaw applications and Big Pharma project work.